Clinical Trial Goal
To find out if PTX-100 is safe and works well to treat CTCL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have CTCL that has relapsed or is refractory
- Do not have lymphoma in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) or autologous (your own cells) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
PTX-100 is a peptidomimetic inhibitor that targets geranylgeranyltransferase type 1 (GGTase-I) on certain cells.
You’ll get treatment in cycles that last 2 to 3 weeks. In each cycle, you'll get:
You’ll get treatment in cycles that last 2 to 3 weeks. In each cycle, you'll get:
- PTX-100– Given as intravenous (IV) infusions 1 time each day for 5 days
You may continue treatment for up to 1.5 years. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1.5 years.
The Food and Drug Administration (FDA) has not yet approved PTX-100.
Contacts
Upaly Bahadure, +61 3 9692 7222, upaly@ptxtherapeutics.com
David Wong, david.wong@ptxtherapeutics.com
Locations
Sponsors
lead: Prescient Therapeutics, Ltd.
